Lineage Cell Therapeutics, Inc.
LCTX
$0.485
-$0.015-3.00%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -24.11% | 168.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -24.11% | 168.39% | |||
| Cost of Revenue | 11.47% | 10.20% | |||
| Gross Profit | -224.39% | 137.90% | |||
| SG&A Expenses | -0.20% | 1.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.71% | 4.73% | |||
| Operating Income | -33.07% | 34.55% | |||
| Income Before Tax | -8.30% | 48.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.30% | 48.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 30.30% | -353.85% | |||
| Net Income | -7.88% | 47.33% | |||
| EBIT | -33.07% | 34.55% | |||
| EBITDA | -34.06% | 35.39% | |||
| EPS Basic | 15.53% | 47.21% | |||
| Normalized Basic EPS | 14.85% | 46.84% | |||
| EPS Diluted | 15.53% | 47.21% | |||
| Normalized Diluted EPS | 14.85% | 46.84% | |||
| Average Basic Shares Outstanding | 27.20% | 0.01% | |||
| Average Diluted Shares Outstanding | 27.20% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
